World Journal of Urology

, Volume 26, Issue 1, pp 45–50 | Cite as

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies

Topic Paper



To summarize the results of the FinnBladder studies of the BTA stat Test in follow-up of bladder cancer and more importantly to provide guidelines for daily clinical practise.


Voided urine samples of 501 patients were obtained prior to cystoscopy and split for culture, cytology and BTA stat testing. The overall sensitivity and specificity for the BTA stat Test were calculated, factors interfering with testing and the role of false positive test result were evaluated.


Out of 501 patients 133 (26.5%) had a bladder cancer recurrence at cystoscopy, of which BTA stat Test detected 71 (53.4%). In the remaining 368 patients, 96 (26.1%) had a positive BTA stat Test result. An additional 9 (16.4%) recurrences were detected at further examinations. The overall sensitivities and specificities for the BTA stat Test and cytology were 56.0, 19.2 and 85.7%, and 98.3%, respectively. Urine infection and past BCG instillations and present instillations of any type caused false positive test result. Out of 79 patients with positive BTA stat Test and negative cystoscopy, 6 (7.6%) had recurrence at next scheduled follow-up cystoscopy.


Although BTA stat Test cannot replace cystoscopy in the follow-up of patients with bladder cancer, it could replace routine cytology especially in patients with low-grade disease. Test should not be used in patients with urine infection, in those having received BCG, or in those with present instillation of any type. In case of positive test result but negative cystoscopy, urine cytology should be obtained as the first line examination. Positive cytology is the indication for further examinations, whereas patients with negative cytology might wait until the next scheduled cystoscopy.


Non-invasive bladder cancer Monitoring BTA stat Tumor marker 



This study was supported by the Medical Research Fund of Seinäjoki Central Hospital.


  1. 1.
    Murphy W (1990) Current status of urinary cytology in evaluation of bladder neoplasms. Hum Pathol 21:886–896PubMedCrossRefGoogle Scholar
  2. 2.
    Umiker W (1964) Accuracy of cytological diagnosis of cancer of the urinary tract. Acta Cytol 8:186–196Google Scholar
  3. 3.
    Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, Tammela TLJ, FinnBladder Group (2002) Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 41(3):284–289PubMedCrossRefGoogle Scholar
  4. 4.
    Sarosdy M, Hudson M, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA, Brunelle SL (1997) Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50:349–353PubMedCrossRefGoogle Scholar
  5. 5.
    Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH (2003) Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169(6):1975–1982PubMedCrossRefGoogle Scholar
  6. 6.
    Raitanen M-P, Marttila T, Kaasinen E, Rintala E, Aine R, Tammela TLJ, Finnbladder group (2000) Sensitivity of human complement factor H related protein (the BTA stat Test) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 163:1689PubMedCrossRefGoogle Scholar
  7. 7.
    Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I (1999) Noninvasive detection of bladder cancer with the BTA stat test. J Urol 161:443–446PubMedCrossRefGoogle Scholar
  8. 8.
    Boman H, Hedelin H, Holmäng S (2002) Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 167:80–83PubMedCrossRefGoogle Scholar
  9. 9.
    Raitanen M-P, Tammela TLJ (1999) Specificity of human complement factor H related protein test (Bard BTA stat test). Scand J Urol Nephrol 33:234–236PubMedCrossRefGoogle Scholar
  10. 10.
    Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162:53–57PubMedCrossRefGoogle Scholar
  11. 11.
    Oge O, Atsü N, Sahin A, Ozen H (2000) Comparison of BTA stat and NMP 22 tests in the detection of bladder cancer. Scand J Urol Nephrol 34(6):349–351PubMedCrossRefGoogle Scholar
  12. 12.
    Raitanen M-P, Marttila T, Nurmi M, Ala-Opas M, Nieminen P, Aine R, Tammela TLJ, Finnbladder group (2001) Human complement factor H related protein (BTA stat) test in monitoring of bladder cancer. J Urol 165:374–377PubMedCrossRefGoogle Scholar
  13. 13.
    Raitanen MP, Kaasinen E, Lukkarinen O, Kauppinen R, Viitanen J, Liukkonen T, Tammela TLJ, Finbladder group (2001) Analysis of false-positive BTA stat test result in patients followed-up for bladder cancer 57(4):680–684Google Scholar
  14. 14.
    Raitanen M-P, Hellström P, Marttila T, Korhonen H, Talja M, Ervasti J, Tammela TLJ, The Finnbaldder Group (2001) Effect of intravesical instillation on human complement factor H related protein (BTA stat) test. Eur Urol 40:422–426PubMedCrossRefGoogle Scholar
  15. 15.
    Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, Bassi P, Boccon-Gipod L, Ravery V, Treiber U (1999) Comparison of the BTA stat Test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of baldder cancer. Eur Urol 35:1:52–56CrossRefGoogle Scholar
  16. 16.
    Toma MI, Friedrich MG, Hautmann SH, Jäkel KT, Erbersdobler A, Hellstern A, Huland H (2004) Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 22:145–149PubMedCrossRefGoogle Scholar
  17. 17.
    Schmitz-Dräger BJ, Tirsar L-A, Schmitz-Dräger C, Dörsam J, Mellan Z, Bismarck E, Ebert T (2007) Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol. doi: 10.1007/s00345-007-0228-x
  18. 18.
    Raitanen MP, Kaasinen E, Rintala E, Hansson E, Nieminen P, Aine R, Tammela TLJ, The Finnbladder group (2001) Prognostic utility of human complement factor H related protein test (the BTA stat Test). Br J Cancer 85(4):552–556PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of SurgerySeinäjoki Central HospitalSeinäjokiFinland

Personalised recommendations